Its role was further strengthened by the AUGUSTUS trial, where apixaban combined with a P2Y12 inhibitor (without aspirin) in patients with AF undergoing PCI reduced bleeding while preserving ischemic efficacy [97]. The gene discussed is P2RY12; the disease is atrial fibrillation.